Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Primary Health Properties still the preferred bidder for Assura, says Shore Capital

(Sharecast News) - Shore Capital has kept a 'buy' rating on healthcare real estate firm Primary Health Properties, saying the company is "still in the mix" over the bidding war for Assura and remains the preferable alternative to the latest offer from KKR and Stonepeak. Assura announced on 9 April that it had reached an agreement with KKR and Stonepeak (together, Sana Bidco) over a 49.4p-a-share cash offer, after rejecting a cash-and-shares offer from PHP equivalent to 46.2p. The company then had to extend the deadline for the posting of a scheme document until 21 May.

However, Shore Capital hailed the synergy benefits from a potential PHP-Assura merger, comprising operational cost efficiencies and the benefits of scale in sourcing services and financing, as well as placing the combined group in good stead amid NHS reforms and accelerating rental growth.

Meanwhile, the shares element of PHP's offer represents "significant value upside" for Assura shareholders if they stay invested - especially given a predicted re-rating of the sector as interest rates fall further.

"[PHP's] offer has improved materially since announced in April following an appreciation of the PHP share price and is now worth 48.1p per Assura share - before synergy benefits and the re-rating potential," Shore Capital said.

"We believe shareholders should support the merger which would create a new powerhouse in a sector with attractive long-term growth prospects while also retaining domestic ownership of critical UK infrastructure. The merger would create the UK's largest healthcare REIT bringing together highly complementary primary care property portfolios, both focused on modern, long-term leased NHS-anchored facilities."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.